Serina Therapeutics, Inc. (SER): Cost of Revenue
Older than the company's other figures. The latest Cost of Revenue is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.
$40.0K
Year ended 2023-12-31
+15.4%
3-year compound annual growth
-35.7%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2023-12-31 | $40.0K | +207.7% | 2024-03-22, From 2023-01-01 |
| 2022-12-31 | $13.0K | -31.6% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $19.0K | -26.9% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $26.0K | -89.3% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $244.0K | -33.0% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $364.0K | +116.7% | 2020-03-31, From 2018-01-01 |
| 2017-12-31 | $168.0K | n/a | 2019-04-01, From 2017-01-01 |